Lantheus Holdings, Inc. Amends Credit Agreement, Extending Maturity Date to 2029

On December 19, 2024, Lantheus Holdings, Inc. (NASDAQ: LNTH) and its subsidiary Lantheus Medical Imaging, Inc. (LMI) announced the execution of a First Amendment to Credit Agreement. The amendment, made in conjunction with certain subsidiaries and Citizens Bank, N.A., as administrative agent and collateral agent, modifies the existing Credit Agreement dated December 2, 2022.

One of the key changes resulting from the Amendment is the extension of the maturity date from December 2, 2027, to December 19, 2029. Additionally, the amendment increases the Revolving Commitment from $350,000,000 to $750,000,000. This amendment allows LMI to boost the Revolving Commitment by an additional $350,000,000. The revised terms also include adjustments to the margins based on LMI’s Total Net Leverage Ratio, impacting the calculation of interest for the Revolving Loans. Moreover, the maximum unused commitment fee has been decreased from 0.35% per annum to 0.30% per annum.

While the above overview provides a summary of the Amendment, it is essential to note that the details of the changes are fully outlined in Exhibit 10.1 attached to Lantheus Holdings, Inc.’s current report on Form 8-K, filed with the Securities and Exchange Commission.

The Amendment falls under Item 1.01 of the current report, designated as “Entry Into a Material Definitive Agreement.” Furthermore, as per Item 2.03, it denotes the “Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.”

The filed report includes the necessary financial statements and exhibits. Exhibit 10.1 features the First Amendment to Credit Agreement, dated December 19, 2024, highlighting changes among Lantheus Medical Imaging, Inc., Lantheus Holdings, Inc., relevant lenders, and Citizens Bank, N.A., as the administrative and collateral agent. Additionally, Exhibit 104 encompasses the Cover Page Interactive Data File, embedded within the Inline XBRL document.

Lastly, the Signing Officer of Lantheus Holdings, Inc., Daniel Niedzwiecki, Chief Administrative Officer, and General Counsel, signed the report on behalf of the company on December 23, 2024. The completion and submission of this current report fulfill the obligations imposed by the Securities Exchange Act of 1934.

Please note this news update is based on the details disclosed in the 8-K filing by Lantheus Holdings, Inc. for public review and information.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lantheus’s 8K filing here.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.